Silexion Therapeutics Ltd. and Moringa Acquisition Corp unveil business combination
Silexion Therapeutics Ltd., an oncology-focused biotechnology company based in Israel, has successfully completed a business combination with Moringa Acquisition Corp, a publicly traded SPAC.
The newly formed entity, Silexion Therapeutics Corp, will begin trading on Nasdaq from August 16, 2024.
This merger aims to advance Silexion’s mission of developing innovative treatments for cancers driven by the KRAS oncogene, with a focus on their promising lead candidate for locally advanced pancreatic cancer.
Herzog Fox & Neeman represented Silexion, led by Ory Nacht and assisted by Michal Herzfeld, Ron Ben-Menachem, Joshua Ravitz, Efrat Tzur, David Azimov, and Danielle Janeli, with the support of the Tax team, Dr. Ehab Farah and Shachar Porat, among others.
Meitar and Greenberg Traurig, LLP advised Moringa.
